Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

NCT01554618 · Completed

Last updated 2026-05-28

This clinical trial tested the safety and effects of once-weekly exenatide injections in adolescents with type 2 diabetes to see how it affects their blood sugar levels over 24 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 84 people

Who can join Ages 10–17 · all sexes

Timeline Started 2011-12 · est. completion 2021-05

Where 35 sites · Bulgaria, Hungary, Israel, Kuwait, Mexico, Ukraine, United States

What this study is testing ClinicalTrials.gov NCT01554618 ↗

Description as written by the study sponsor.

The study examines the Safety and efficacy study of exenatide once weekly in children and adolescents with type 2 diabetes

Treatments tested

Exenatide Once Weekly also known as BYDUREON Drug

2 mg exenatide once weekly
Placebo Drug

Placebo

Main thing measured	Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) to Week 24 (Controlled Assessment Period)
Sponsor	AstraZeneca
Conditions studied	Children and Adolescent With Type 2 Diabetes
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01554618 ↗